Tsuchimoto Kim R, CFO, reported a transaction classified as exercise at Monopar Therapeutics involving 9957.000000 shares for an estimated $0.00. Reported holdings after the transaction were 95556.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
Represents shares acquired on vesting and settlement of restricted stock units.
Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU…
On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU…
On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU…
On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, an…
0 other filings
0 recent txs